|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DDX6 |
Gene summary for DDX6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DDX6 | Gene ID | 1656 |
| Gene name | DEAD-box helicase 6 | |
| Gene Alias | HLR2 | |
| Cytomap | 11q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | B2R858 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1656 | DDX6 | LZE4T | Human | Esophagus | ESCC | 2.35e-27 | 7.90e-01 | 0.0811 |
| 1656 | DDX6 | LZE5T | Human | Esophagus | ESCC | 2.55e-08 | 4.93e-01 | 0.0514 |
| 1656 | DDX6 | LZE7T | Human | Esophagus | ESCC | 1.84e-11 | 7.88e-01 | 0.0667 |
| 1656 | DDX6 | LZE8T | Human | Esophagus | ESCC | 4.22e-16 | 4.27e-01 | 0.067 |
| 1656 | DDX6 | LZE20T | Human | Esophagus | ESCC | 5.87e-13 | 5.03e-01 | 0.0662 |
| 1656 | DDX6 | LZE21D1 | Human | Esophagus | HGIN | 9.51e-03 | 4.00e-01 | 0.0632 |
| 1656 | DDX6 | LZE22D1 | Human | Esophagus | HGIN | 1.24e-08 | 7.85e-01 | 0.0595 |
| 1656 | DDX6 | LZE22T | Human | Esophagus | ESCC | 1.08e-19 | 1.60e+00 | 0.068 |
| 1656 | DDX6 | LZE24T | Human | Esophagus | ESCC | 1.12e-31 | 7.31e-01 | 0.0596 |
| 1656 | DDX6 | LZE21T | Human | Esophagus | ESCC | 1.99e-09 | 4.13e-01 | 0.0655 |
| 1656 | DDX6 | LZE6T | Human | Esophagus | ESCC | 1.83e-15 | 4.01e-01 | 0.0845 |
| 1656 | DDX6 | P1T-E | Human | Esophagus | ESCC | 2.68e-09 | 5.13e-01 | 0.0875 |
| 1656 | DDX6 | P2T-E | Human | Esophagus | ESCC | 6.77e-47 | 8.05e-01 | 0.1177 |
| 1656 | DDX6 | P4T-E | Human | Esophagus | ESCC | 3.63e-42 | 1.04e+00 | 0.1323 |
| 1656 | DDX6 | P5T-E | Human | Esophagus | ESCC | 1.42e-28 | 5.02e-01 | 0.1327 |
| 1656 | DDX6 | P8T-E | Human | Esophagus | ESCC | 1.64e-39 | 7.44e-01 | 0.0889 |
| 1656 | DDX6 | P9T-E | Human | Esophagus | ESCC | 3.10e-27 | 5.73e-01 | 0.1131 |
| 1656 | DDX6 | P10T-E | Human | Esophagus | ESCC | 5.95e-42 | 8.09e-01 | 0.116 |
| 1656 | DDX6 | P11T-E | Human | Esophagus | ESCC | 1.07e-24 | 8.68e-01 | 0.1426 |
| 1656 | DDX6 | P12T-E | Human | Esophagus | ESCC | 1.73e-40 | 7.79e-01 | 0.1122 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003406322 | Oral cavity | EOLP | stress granule assembly | 11/2218 | 26/18723 | 8.86e-05 | 1.04e-03 | 11 |
| GO:006096422 | Oral cavity | EOLP | regulation of gene silencing by miRNA | 15/2218 | 49/18723 | 3.73e-04 | 3.38e-03 | 15 |
| GO:200063723 | Oral cavity | EOLP | positive regulation of gene silencing by miRNA | 11/2218 | 30/18723 | 3.99e-04 | 3.56e-03 | 11 |
| GO:006014822 | Oral cavity | EOLP | positive regulation of posttranscriptional gene silencing | 11/2218 | 31/18723 | 5.53e-04 | 4.71e-03 | 11 |
| GO:006014723 | Oral cavity | EOLP | regulation of posttranscriptional gene silencing | 15/2218 | 52/18723 | 7.52e-04 | 6.05e-03 | 15 |
| GO:006096623 | Oral cavity | EOLP | regulation of gene silencing by RNA | 15/2218 | 53/18723 | 9.35e-04 | 7.11e-03 | 15 |
| GO:006096813 | Oral cavity | EOLP | regulation of gene silencing | 20/2218 | 81/18723 | 9.93e-04 | 7.46e-03 | 20 |
| GO:00339629 | Oral cavity | EOLP | P-body assembly | 8/2218 | 21/18723 | 1.87e-03 | 1.21e-02 | 8 |
| GO:001603233 | Oral cavity | NEOLP | viral process | 101/2005 | 415/18723 | 1.08e-15 | 5.85e-13 | 101 |
| GO:001905834 | Oral cavity | NEOLP | viral life cycle | 77/2005 | 317/18723 | 3.13e-12 | 5.82e-10 | 77 |
| GO:000641734 | Oral cavity | NEOLP | regulation of translation | 97/2005 | 468/18723 | 9.94e-11 | 1.05e-08 | 97 |
| GO:000961531 | Oral cavity | NEOLP | response to virus | 80/2005 | 367/18723 | 3.70e-10 | 3.14e-08 | 80 |
| GO:003052231 | Oral cavity | NEOLP | intracellular receptor signaling pathway | 61/2005 | 265/18723 | 5.22e-09 | 2.87e-07 | 61 |
| GO:005160731 | Oral cavity | NEOLP | defense response to virus | 57/2005 | 265/18723 | 1.97e-07 | 6.55e-06 | 57 |
| GO:014054631 | Oral cavity | NEOLP | defense response to symbiont | 57/2005 | 265/18723 | 1.97e-07 | 6.55e-06 | 57 |
| GO:003210323 | Oral cavity | NEOLP | positive regulation of response to external stimulus | 81/2005 | 427/18723 | 2.04e-07 | 6.74e-06 | 81 |
| GO:000283131 | Oral cavity | NEOLP | regulation of response to biotic stimulus | 65/2005 | 327/18723 | 5.93e-07 | 1.74e-05 | 65 |
| GO:001982721 | Oral cavity | NEOLP | stem cell population maintenance | 34/2005 | 131/18723 | 6.89e-07 | 1.93e-05 | 34 |
| GO:009872721 | Oral cavity | NEOLP | maintenance of cell number | 34/2005 | 134/18723 | 1.21e-06 | 3.13e-05 | 34 |
| GO:003406331 | Oral cavity | NEOLP | stress granule assembly | 11/2005 | 26/18723 | 3.46e-05 | 5.12e-04 | 11 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301810 | Esophagus | HGIN | RNA degradation | 27/1383 | 79/8465 | 7.73e-05 | 9.00e-04 | 7.15e-04 | 27 |
| hsa0301815 | Esophagus | HGIN | RNA degradation | 27/1383 | 79/8465 | 7.73e-05 | 9.00e-04 | 7.15e-04 | 27 |
| hsa0301824 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
| hsa0301834 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
| hsa03018 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
| hsa030181 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
| hsa030182 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| hsa030183 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| hsa030189 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
| hsa0301814 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
| hsa0301823 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
| hsa0301833 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
| hsa0301841 | Oral cavity | EOLP | RNA degradation | 22/1218 | 79/8465 | 1.33e-03 | 4.80e-03 | 2.83e-03 | 22 |
| hsa0301851 | Oral cavity | EOLP | RNA degradation | 22/1218 | 79/8465 | 1.33e-03 | 4.80e-03 | 2.83e-03 | 22 |
| hsa0301861 | Oral cavity | NEOLP | RNA degradation | 18/1112 | 79/8465 | 1.25e-02 | 4.06e-02 | 2.56e-02 | 18 |
| hsa0301871 | Oral cavity | NEOLP | RNA degradation | 18/1112 | 79/8465 | 1.25e-02 | 4.06e-02 | 2.56e-02 | 18 |
| hsa030188 | Prostate | BPH | RNA degradation | 29/1718 | 79/8465 | 5.17e-04 | 2.67e-03 | 1.65e-03 | 29 |
| hsa0301813 | Prostate | BPH | RNA degradation | 29/1718 | 79/8465 | 5.17e-04 | 2.67e-03 | 1.65e-03 | 29 |
| hsa0301822 | Prostate | Tumor | RNA degradation | 30/1791 | 79/8465 | 4.48e-04 | 2.35e-03 | 1.46e-03 | 30 |
| hsa0301832 | Prostate | Tumor | RNA degradation | 30/1791 | 79/8465 | 4.48e-04 | 2.35e-03 | 1.46e-03 | 30 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DDX6 | SNV | Missense_Mutation | c.602N>C | p.Gly201Ala | p.G201A | P26196 | protein_coding | deleterious(0) | possibly_damaging(0.824) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| DDX6 | SNV | Missense_Mutation | c.1104N>C | p.Met368Ile | p.M368I | P26196 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| DDX6 | SNV | Missense_Mutation | c.952N>A | p.Glu318Lys | p.E318K | P26196 | protein_coding | deleterious(0.04) | possibly_damaging(0.665) | TCGA-D8-A1XJ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| DDX6 | SNV | Missense_Mutation | c.1198A>T | p.Ile400Leu | p.I400L | P26196 | protein_coding | deleterious(0) | possibly_damaging(0.847) | TCGA-D8-A1XV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DDX6 | insertion | Frame_Shift_Ins | novel | c.38_39dupGT | p.Leu14ValfsTer9 | p.L14Vfs*9 | P26196 | protein_coding | TCGA-A7-A26F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | ||
| DDX6 | insertion | Frame_Shift_Ins | novel | c.42_43insAGGCAGGTAGATCACGAGGTCAAAAGTTTGAGGC | p.Ser15ArgfsTer50 | p.S15Rfs*50 | P26196 | protein_coding | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| DDX6 | insertion | Frame_Shift_Ins | novel | c.962_963insCTTTAGAAGACTTACTCTGGCACTCATAC | p.Lys321AsnfsTer24 | p.K321Nfs*24 | P26196 | protein_coding | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
| DDX6 | SNV | Missense_Mutation | novel | c.220N>G | p.Lys74Glu | p.K74E | P26196 | protein_coding | tolerated(0.46) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DDX6 | insertion | Frame_Shift_Ins | novel | c.1036_1037insTAGAA | p.Arg346LeufsTer7 | p.R346Lfs*7 | P26196 | protein_coding | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD | ||
| DDX6 | insertion | Nonsense_Mutation | novel | c.1035_1036insGGAGAATGA | p.Gln345_Arg346insGlyGluTer | p.Q345_R346insGE* | P26196 | protein_coding | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |